ARWR

Business Context and Reporting Period

Company: Arrowhead Pharmaceuticals, Inc. (ARWR)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2024
Business Overview: Arrowhead is a clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics to treat intractable diseases by silencing disease-causing genes. The company utilizes its proprietary Targeted RNAi Molecule (TRiM) platform to deliver therapies to tissues beyond the liver, including the lung, CNS, muscle, and adipose tissue.

Key Pipeline Status:

• Plozasiran (ARO-APOC3): Lead candidate for familial chylomicronemia syndrome (FCS). Completed Phase 3 PALISADE trial meeting primary and key secondary endpoints. New Drug Application (NDA) filed with the FDA on November 16, 2024. Commercial launch expected in 2025 pending approval.
• Zodasiran (ARO-ANG3): Phase 2b trials for mixed dyslipidemia and homozygous familial hypercholesterolemia.
• Fazirsiran (ARO-AAT): Phase 3 trials for alpha-1 antitrypsin deficiency (AATD) in collaboration with Takeda.
• Olpasiran (ARO-LPA): Phase 3 cardiovascular outcomes trial (OCEAN(a)) completed enrollment; licensed to Amgen.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 98.5% to $3.6 million from $240.7 million. This was primarily due to the completion of performance obligations under the Takeda collaboration agreement (fazirsiran) and the Horizon agreement, which were fully recognized in prior periods. The GSK-HBV agreement contributed $2.7 million in upfront revenue.
• Increased Net Loss: Net loss widened to $599.5 million from $205.3 million. The increase was driven by a significant drop in revenue and a 43% increase in R&D expenses ($152.7 million increase) due to the progression of multiple candidates into later-stage clinical trials and expanded discovery efforts.
• Capital Structure Changes:
  • Equity: Issued 15.8 million shares in January 2024, raising net proceeds of $429.3 million.
  • Debt: Entered a $500 million senior secured term loan facility with Sixth Street Lending Partners in August 2024, funding $400 million with net proceeds of $388.9 million.
• Investment Portfolio: Available-for-sale securities increased by $285.6 million to $578.3 million, reflecting the deployment of capital raised from equity and debt financing.

Guidance, Outlook, and Risks

Management Commentary & Outlook:

• Liquidity: Management expects sufficient liquidity to fund operations for at least the next 12 months based on current cash, investments, and the new credit facility.
• Commercialization: The company anticipates the first commercial launch of plozasiran in 2025, contingent upon FDA acceptance of the NDA and successful review.
• Strategic Goal: Aiming to have 20 individual drugs (partnered or wholly owned) in clinical trials or on the market by 2025.

Recent Subsequent Events (Post-Sept 30, 2024):

• Sarepta Collaboration: Entered an exclusive license and collaboration agreement with Sarepta Therapeutics for muscle, CNS, and lung programs. Expected upfront payment of $500 million plus $250 million in annual installments and significant milestones.
• Private Placement: Agreed to sell approximately $325 million of common stock to an affiliate of Sarepta and $25 million of pre-funded warrants to an institutional investor.

Key Risks:

• Regulatory Approval: No products are currently approved. Success depends on FDA/EMA approval of plozasiran and other candidates.
• Financial Condition: History of net losses; requires substantial additional funding for R&D and commercialization. The new debt facility includes covenants restricting asset sales and licensing of core IP.
• Partnership Dependence: Revenue and milestone payments are heavily dependent on the actions of partners (Amgen, GSK, Takeda, Sarepta).

Investor Verification Checklist

• NDA Status: Verify the FDA's decision on the filing acceptance of the plozasiran NDA for FCS and the timeline for the Prescription Drug User Fee Act (PDUFA) date.
• Debt Covenants: Review the specific liquidity thresholds and negative covenants in the Sixth Street Credit Facility to ensure compliance does not restrict future strategic transactions.
• Sarepta Deal Closing: Confirm the closing of the Sarepta collaboration and stock purchase agreement, including the receipt of the $500 million upfront payment and $325 million equity investment.
• R&D Burn Rate: Monitor the trajectory of R&D expenses as the company scales up for potential commercialization of plozasiran and advances other Phase 3 programs.
• Manufacturing Capacity: Verify the commissioning and validation status of the new Verona, Wisconsin GMP manufacturing facility, which is critical for commercial supply.